What to expect:
Interventions to address cardiovascular risk in patients with obesity
Leading medical associations are calling on primary care practitioners (PCPs) to be proactive in preventing cardiovascular disease (CVD) to reduce the number of premature deaths from heart attacks and strokes.1–3 Major international guidelines now emphasise the role of obesity in cardiovascular disease and advocate healthy lifestyles: via nutrition, exercise, weight loss, smoking cessation and management of dyslipidaemia, hypertension and/or diabetes.1–3 GPs should be promoting these goals to their patients and prescribing appropriate, evidence-based medicines where indicated.3,4
Obesity in CVD treatment guidelines
Guidelines recommend weight loss in patients with cardiovascular disease and obesity 1,2
Recent statements by leading cardiology societies in both Europe and the United States are emphasising the need for obesity and weight loss to be given a higher priority in the management of patients with established cardiovascular disease (CVD).1,2
In statements published in 2021, both the European Society of
Cardiology (ESC) and the American Heart Association (AHA)
have called for better management of patients with obesity and CVD and
for all such patients to be counselled on nutrition and physical
activity and other targeted weight loss interventions, including
weight loss medications.1,2
In its most recent statement on obesity and CVD, its first update in
15 years, the American Heart Association (AHA) concludes that
the treatment and management of patients with obesity and CVD needs to
be improved.1 The statement confirms obesity as a complex,
multifactorial chronic disease linked to cardiovascular disease (CVD)
and that a 10% or greater weight loss results in significant
reductions in cardiovascular events.1
The AHA has just updated its criteria for assessing cardiovascular health from the well-known ‘life’s simple 7’ to ‘life’s essential 8’. It now measures obesity as a risk factor for cardiovascular disease on par with high LDL cholesterol, hypertension and elevated blood glucose.8
Obesity is a risk factor for CVD on par with high LDL, blood pressure and blood sugar5
The European Society of Cardiology has also criticized the lack of priority given to weight loss in cardiovascular disease. In a statement published in 2021, the ESC appealed for more help to be given to heart patients to lose weight.6 It cited a study of pooled data on 10,000 patients with CVD from the EUROASPIRE IV (2012 to 2013) and EUROASPIRE V (2016 to 2017) studies conducted in 29 European countries. Fewer than 20 percent of the patients had a healthy BMI at the time of their CVD event and more than a third of the patients with obesity said they had not received advice on physical activity or nutrition, with nearly one in five saying they had not been informed that they were overweight.6 The pooled data study found that 86 percent of patients with obesity did not lose weight following their event, and that 14 percent of patients who had overweight at the time of their event had obesity by the time of their 16-month follow up.7 The study authors concluded that obesity had “not been considered a serious medical problem requiring attention” in these patients.6
The potential for obesity management for secondary prevention of cardiac events in patients who have already been diagnosed with coronary heart disease was emphasised in the study.7 The authors recommended that cardiac rehabilitation programmes should specifically target weight loss interventions, including making use of telemedicine and appropriate weight loss medications.7
Recommended interventions to reduce cardiovascular disease risks
Evidence-based recommended interventions and therapies to reduce the risks of atherosclerotic cardiovascular disease (ASCVD) include medications to control hypertension, dyslipidaemia, diabetes and coagulation as well as lifestyle modifications. 2,8
Source: Piepoli MF, Hoes A, Agewall S, et al. 2 Patel K, Pandey A and de Lemos A.8
Looking to the future for patients with cardiovascular disease (CVD)
In spite of the evidence-based therapies to mitigate CVD mentioned above, individuals, especially those who have already experienced a cardiac event, still face residual risk for another CVD event.8
New drugs have recently been developed that target new pathophysiological pathways in CVD.8 Clinical trials have shown these can reduce event rates, and in some cases all-cause and cardiovascular mortality.8 Referring patients on to a cardiologist can allow them to be assessed for some of these medications.8
For more information on how to communicate risk in cardiovascular assessments, click here.
- Powell-Wiley T, Poirier P, Burke L, et al. Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation. 2021;143:e984–e1010.
- Piepoli MF, Hoes A, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–81.
- World Health Organization. 2021. Cardiovascular diseases. Fact sheet. Available at: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Last accessed: August 2022.
- National Heart Lung and Blood Institute. New Report. Available at: https://www.nhlbi.nih.gov/news/2021/cardiovascular-disease-rise-we-know-how-curb-it-weve-done-it. Last accessed: August 2022.
- Lloyd-Jones D, Allen N, Anderson C, et al. Life’s essential 8: Updating and enhancing the American Heart Association’s construct of cardiovascular health: A presidential advisory from the American Heart Association. Circulation. 2022;146:e18–e43. Available at: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001078. Last accessed: September 2022.
- European Society of Cardiology. Press statement. July 28, 2021. Available at: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Heart-patients-need-more-help-to-lose-weight. Last accessed: August 2022.
- De Bacquer D, Jennings C, Mirrakhimov E, et al. Potential for optimizing management of obesity in the secondary prevention of coronary heart disease. Eur Heart J. 2021. Doi: 10.1093/ehjqcco/qcab043.
- Patel K, Pandey A and de Lemos A. Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine. Circulation. 2018;137:2551–2553.
HQ22OB00147, Approval date: October 2022
You are leaving RethinkObesity.Global
The site you are entering is not the property of, nor managed by, Novo Nordisk. Novo Nordisk assumes no responsibility for the content of sites not managed by Novo Nordisk. Furthermore, Novo Nordisk is not responsible for, nor does it have control over, the privacy policies of these sites.
Find your local HCP portal
At Novo Nordisk we want to provide Healthcare Professionals (HCPs) with scientific information, resources and tools.